|
JP2007501021A
(ja)
*
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
|
DE102004063494A1
(de)
*
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
HUE028179T2
(en)
|
2006-01-12 |
2016-12-28 |
Alexion Pharma Inc |
Antibodies to OX-2 / CD200 and their use
|
|
PL3167888T3
(pl)
|
2006-03-15 |
2024-08-26 |
Alexion Pharmaceuticals, Inc. |
Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
|
|
LT2894165T
(lt)
|
2008-11-10 |
2023-03-10 |
Alexion Pharmaceuticals, Inc. |
Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
|
|
WO2010088522A2
(en)
*
|
2009-01-30 |
2010-08-05 |
Ab Biosciences, Inc. |
Novel lowered affinity antibodies and uses therefor
|
|
JP2012531212A
(ja)
|
2009-07-03 |
2012-12-10 |
アビペップ ピーティーワイ リミテッド |
イムノコンジュゲート及びその作製方法
|
|
EP2499494B1
(en)
|
2009-11-09 |
2017-03-08 |
Alexion Pharmaceuticals, Inc. |
Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
|
|
SG181814A1
(en)
|
2009-12-23 |
2012-07-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them 2
|
|
CA2786692A1
(en)
|
2010-01-11 |
2011-07-14 |
Alexion Pharmaceuticals, Inc. |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
|
EP2824111B1
(en)
|
2010-04-30 |
2017-03-22 |
Alexion Pharmaceuticals, Inc. |
Anti-C5A Antibodies and Methods for Using the Antibodies
|
|
US9815890B2
(en)
|
2010-06-22 |
2017-11-14 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the C3d fragment of complement component 3
|
|
EP2596022A4
(en)
|
2010-07-20 |
2014-11-05 |
Cephalon Australia Pty Ltd |
SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
|
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
|
US9624294B2
(en)
|
2011-03-14 |
2017-04-18 |
Cellmid Limited |
Antibody recognizing N-domain of midkine
|
|
EP2699597B1
(en)
|
2011-04-21 |
2016-06-01 |
Garvan Institute of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
|
JP6187777B2
(ja)
|
2011-06-13 |
2017-08-30 |
シーエスエル、リミテッド |
Ｇ−ｃｓｆｒに対する抗体およびその使用
|
|
MX2014003689A
(es)
|
2011-09-30 |
2014-12-05 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos contra tl1a y sus usos.
|
|
WO2013059886A1
(en)
|
2011-10-28 |
2013-05-02 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
|
EP2895203A4
(en)
*
|
2012-06-15 |
2016-09-28 |
Imaginab Inc |
ANTIGENBINDING CONSTRUCTS FOR CD3
|
|
US9840559B2
(en)
|
2013-02-01 |
2017-12-12 |
The Regents Of The University Of California |
Anti-CD83 antibodies and use thereof
|
|
CN104995211B
(zh)
|
2013-02-07 |
2019-09-13 |
Csl有限公司 |
Il-11r结合蛋白及其应用
|
|
JP6612246B2
(ja)
|
2013-11-28 |
2019-11-27 |
シーエスエル、リミテッド |
腎症を処置する方法
|
|
US10543270B2
(en)
|
2013-12-18 |
2020-01-28 |
Csl Limited |
Methods of treating wounds in a diabetic subject
|
|
US10584175B2
(en)
|
2014-10-23 |
2020-03-10 |
La Trobe University |
FN14-binding proteins and uses thereof
|
|
WO2016061617A1
(en)
|
2014-10-23 |
2016-04-28 |
Dendrocyte Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
|
ES2717308T3
(es)
|
2014-12-06 |
2019-06-20 |
Gemoab Monoclonals Gmbh |
Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
|
|
NZ732073A
(en)
*
|
2014-12-08 |
2019-04-26 |
1Globe Biomedical Co Ltd |
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
|
AU2015367224B2
(en)
|
2014-12-19 |
2020-12-10 |
Monash University |
IL-21 antibodies
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
US10894834B2
(en)
|
2015-11-27 |
2021-01-19 |
Csl Limited |
CD131 binding proteins
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
WO2018053597A1
(en)
|
2016-09-23 |
2018-03-29 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
CN111670198B
(zh)
|
2017-09-11 |
2023-12-15 |
莫纳什大学 |
人凝血酶受体par4的结合蛋白
|
|
WO2019075519A1
(en)
|
2017-10-18 |
2019-04-25 |
Csl Limited |
HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
|
|
EP3713962A4
(en)
*
|
2017-11-21 |
2021-08-25 |
Novartis AG |
TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENS AND THEIR USE
|
|
CA3081770A1
(en)
|
2017-11-29 |
2019-06-06 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
|
WO2019114768A1
(en)
|
2017-12-12 |
2019-06-20 |
Biocytogen Jiangsu Co., Ltd. |
GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
|
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
|
WO2019178645A1
(en)
|
2018-03-23 |
2019-09-26 |
Csl Limited |
Method of treating asthma
|
|
SI3793586T1
(sl)
|
2018-05-16 |
2024-07-31 |
Csl Limited |
Različice receptorja za topni komplement tipa 1 in njihova uporaba
|
|
AU2019302642B2
(en)
|
2018-07-10 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Modifying binding molecules to minimize pre-existing interactions
|
|
US12428484B2
(en)
|
2018-12-06 |
2025-09-30 |
Alexion Pharmaceuticals, Inc. |
Anti-ALK2 antibodies and uses thereof
|
|
CN109776683B
(zh)
*
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
CN111909268B
(zh)
*
|
2019-05-07 |
2022-04-19 |
北京天成新脉生物技术有限公司 |
低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
|
|
IL322315A
(en)
|
2019-05-14 |
2025-09-01 |
Provention Bio Inc |
Methods and preparations for preventing type 1 diabetes
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
WO2021119761A1
(en)
|
2019-12-20 |
2021-06-24 |
Hudson Institute of Medical Research |
Cxcl10 binding proteins and uses thereof
|
|
CN116249549A
(zh)
*
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
|
US12583929B2
(en)
|
2020-06-04 |
2026-03-24 |
CSL Innovation Pty Ltd |
Method of treating acute respiratory distress syndrome
|
|
AU2021287998B2
(en)
|
2020-06-11 |
2026-03-12 |
Benaroya Research Institute At Virginia Mason |
Methods and compositions for preventing type 1 diabetes
|
|
WO2022013613A2
(en)
|
2020-07-17 |
2022-01-20 |
Onena Medicines S.L. |
Antibodies against lefty proteins
|
|
CN114656562B
(zh)
*
|
2020-12-23 |
2023-11-03 |
北京天广实生物技术股份有限公司 |
结合人和猴cd3的抗体及其应用
|
|
US12565529B2
(en)
|
2021-05-24 |
2026-03-03 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
|
US20260061078A1
(en)
|
2022-08-31 |
2026-03-05 |
Universität Zürich |
Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers
|
|
KR20260036321A
(ko)
|
2023-07-05 |
2026-03-16 |
씨에스엘 이노베이션 피티와이 엘티디 |
겸상적혈구병의 합병증을 치료하거나 예방하는 방법
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|